Breadcrumb

What's New at the RI-MUHC ?

When is dead really dead?

Dr. Sam Shemie leads the death prediction and physiology after removal of therapy study (DePPaRT study)

RI-MUHC researchers support Canada’s efforts to address the COVID-19 pandemic

Drs. Emily McDonald and Todd C. Lee are part of the Canadian Network of COVID-19 Clinical Trials Networks...

Overcoming vaccine hesitancy

Our best hope of charting a course to a post-pandemic world

Early diagnosis is key to prevention of potentially fatal complication in type 1 diabetes

New RI-MUHC study of international data suggests awareness and access to care are key factors in improving...

New study of hydroxychloroquine usage may help personalize lupus treatment

RI-MUHC researchers identify factors associated with poor outcomes for lupus patients

Reaching new heights by working together: Innovative industry partnership

RI-MUHC-led team will use artificial intelligence to improve survival rates of cancer-diagnosed patients

Two studies confirm efficiency of saliva tests for COVID-19

Testing is the cornerstone of the fight against COVID-19, and a test that can be self-administered would greatly increase the options for case...

Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper

New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples

Could an antidepressant slow COVID-19 progression?

RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...

Clinical Innovation Platform at the RI-MUHC announces first member company

Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility

Learn more about the RI-MUHC